21 Apr 2021
Interim report January-March 2021
First quarter 2021 (1 Jan – 31 Mar)• Net sales amounted to SEK 58.3 million (46.5), corresponding to an…
Read moreNews Tag: English
19 Apr 2021
Australian heart preservation study underway
The first patient in an investigator-initiated heart preservation study using XVIVO’s technology was transplanted during the first quarter of 2021 at The Alfred hospital (Melbourne, Australia). The trial includes Australian and New Zealand transplant centers and is investigating if the novel preservation technology may safely extend the transport time for donor hearts, which is ideally limited to four hours using existing processes.
Read more 08 Apr 2021
Conference call on Interim Report
Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the interim report January – March 2021. The presentation will be held in English
Read more 29 Mar 2021
Annual report 2020
Today XVIVO Perfusion AB (publ) publish the Annual Report for 2020. The Annual Report is attached to this…
Read more 15 Mar 2021
Notice to attend the Annual General Meeting in XVIVO Perfusion AB (publ)
The shareholders in XVIVO Perfusion AB (publ), reg. no. 556561-0424 (the “Company” or “XVIVO”), with its registered office in Gothenburg, are hereby invited to the annual general meeting on Thursday 22 April 2021 at 15:00 AM, at The Swedish Exhibition & Congress Centre (Sw. Svenska Mässan) (conference room J2), at Mässans gata 24 in Gothenburg, Sweden.
Read more